Positron-Emission Tomography Clinical Trial
— VALIDATEOfficial title:
Dynamic Wholebody FDG PET/CT - Next Generational Functional Imaging: Optimization and Validation of Data Acquisition
Verified date | February 2022 |
Source | Aarhus University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Quantification of the metabolic rate of glucose from Dynamic Whole-Body PET examinations requires measurements of the time course of the radioactivity concentrations in arterial blood by blood sampling, and in the tissue of interest by dynamic PET. Invasive arterial blood sampling cannot be part of a standard examination, and therefore the blood samples need to be replaced by activity concentrations derived from the PET images, usually from small volumes in the descending aorta or left ventricle. Newly developed scanner software (Siemens) allows automated CT-based identification of blood pool regions and extraction of an image-derived blood input function from the corresponding PET data. However, this automated method needs validation, as it could be prone to systematic errors caused by limited spatial resolution, patient movement, and image reconstruction. We will use invasively measured arterial blood samples as a reference for validation of methods to extract non-invasive PET image-derived input functions and quantify any systematic errors that could propagate to the resulting parametric images.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Patients with a planned clinical standard PET/CT as part of pre-therapeutic staging, response assessment scanning. - Good performance status, which will allow us to obtain informed consent to draw the required arterial blood samples during the examination, and which will permit patients to lay still in the scanner for at least 70 min. Exclusion Criteria: - • Age < 18 or > 85 years - Patients that can not tolerate a PET scan (f.ex: claustrophobia). |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus |
Lead Sponsor | Collaborator |
---|---|
Aarhus University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Validation of current parametric reconstruction protocol | We will perform a correlation of the image derived input function and the input function obtained from blood sampling. This will allow us to confirm that the information obtained by the equipment is accurate enough and can be trusted. | through study completion, an average of 1 year | |
Primary | Time reduction of current parametric reconstruction protocol | After we have validated the image derived input function we will use the data we sampled to construct a "normal population" input function that can be applied to the current protocol. This way we will be able to skip the acquisition on the camera of the input function and be able to only scan the patients at a later period, therefor shortening the acquisition protocol to something more manageable in daily clinic. | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04555642 -
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
|
||
Recruiting |
NCT05004961 -
The Performance of Multi-tracer Multimodality PET in Lymphoma
|
||
Recruiting |
NCT05188872 -
Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE
|
N/A | |
Recruiting |
NCT04983095 -
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05610098 -
Gene Expression Profiles in Spinal Tuberculosis.
|
||
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
Recruiting |
NCT04831541 -
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
|
Early Phase 1 | |
Recruiting |
NCT06188468 -
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors
|
N/A | |
Recruiting |
NCT06017973 -
The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus
|
N/A | |
Recruiting |
NCT03830242 -
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
|
N/A | |
Recruiting |
NCT06387381 -
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
|
Early Phase 1 | |
Recruiting |
NCT05506566 -
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04367948 -
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma
|
N/A | |
Recruiting |
NCT05757804 -
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
|
||
Completed |
NCT05392205 -
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
|
N/A | |
Completed |
NCT03741231 -
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
|
||
Completed |
NCT01035164 -
Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03107663 -
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
|
Phase 1 | |
Recruiting |
NCT03636607 -
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
|
N/A |